CN115281150A - 脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法 - Google Patents
脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法 Download PDFInfo
- Publication number
- CN115281150A CN115281150A CN202210791084.XA CN202210791084A CN115281150A CN 115281150 A CN115281150 A CN 115281150A CN 202210791084 A CN202210791084 A CN 202210791084A CN 115281150 A CN115281150 A CN 115281150A
- Authority
- CN
- China
- Prior art keywords
- spleen
- cell suspension
- lung cancer
- liver metastasis
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010027476 Metastases Diseases 0.000 title claims abstract description 44
- 230000009401 metastasis Effects 0.000 title claims abstract description 43
- 210000004185 liver Anatomy 0.000 title claims abstract description 37
- 210000000952 spleen Anatomy 0.000 title claims abstract description 33
- 239000007924 injection Substances 0.000 title claims abstract description 27
- 238000002347 injection Methods 0.000 title claims abstract description 27
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title claims abstract description 24
- 201000005249 lung adenocarcinoma Diseases 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000010172 mouse model Methods 0.000 title claims abstract description 16
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 26
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 24
- 201000005202 lung cancer Diseases 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000006285 cell suspension Substances 0.000 claims description 22
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 12
- 241000699670 Mus sp. Species 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 238000011503 in vivo imaging Methods 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 238000002271 resection Methods 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 238000013227 male C57BL/6J mice Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 210000001015 abdomen Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 6
- 210000005228 liver tissue Anatomy 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000009456 molecular mechanism Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010027457 Metastases to liver Diseases 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及疾病模型制备技术领域，公开了脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法，包括制备Lewis肺癌细胞悬浮液和切开小鼠脾脏与注射Lewis肺癌细胞悬浮液。本发明首次创新的建立了肺腺癌肝转移小鼠模型，该模型除肝组织外，其余器官均无转移瘤形成，为进一步研究肺腺癌肝转移的分子机制、信号调控途径，以及未来研究和开发抑制或/和阻断肺癌转移的分子靶向药物提供了可靠的动物模型。
Description
技术领域
本发明涉及疾病模型制备技术领域，具体涉及脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法。
背景技术
原发性肺癌是我国最常见的恶性肿瘤，其中非小细胞肺癌(NSCLC)约占85％，肺腺癌(lung adenocarcinoma，LUAD)是NSCLC最常见的组织学亚型，约占肺癌的40％，也是最致命的恶性肿瘤之一。NSCLC的5年生存率为15％，晚期转移性肺癌生存率仅5.5％。肿瘤转移是肿瘤患者死亡的主要原因，占肿瘤相关死亡的95％，并且大多无法治愈。对于NSCLC患者，常见的转移器官包括淋巴结、肝脏、骨和脑组织，其中，约20％的肺癌发生肝脏转移。在发生单器官转移的肺癌中，肝转移患者的预后较差，中位生存期仅3-6个月。目前治疗肝转移性肺癌的策略主要是使用包括手术、肝移植、放疗、抗血管治疗或免疫检查点抑制剂等在内的综合治疗。其中，手术、放疗需要考虑肿瘤个数、大小、生长部位等指征；肝移植在转移性肝癌中的运用仍存在很大争议；抗血管治疗对患者总体生存期的延长存在瓶颈。临床研究提示肝转移是肿瘤免疫治疗疗效差的独立预测因素，肝转移而非其他部位转移可通过调节全身系统性抗肿瘤免疫诱导免疫治疗耐药。
近年来，免疫治疗作为单药或者联合化疗已经成为晚期转移性NSCLC患者的一线标准治疗。然而，相当部分患者初始治疗无效，仅约20％的LUAD患者从免疫治疗中获益，并且这些患者中的大多数会出现继发性耐药。临床研究提示肝转移是免疫治疗肿瘤治疗疗效差的独立预测因素，肝转移而非其他部位转移可通过调节全身系统性抗肿瘤免疫诱导免疫治疗耐药。对于这种免疫治疗敏感性或耐药性问题也是当前研究的热点，目前认为肿瘤组织内免疫细胞的浸润不足、免疫抑制微环境的形成是导致免疫治疗不响应或耐药的关键因素。因此，运用免疫完整小鼠建立LUAD肝脏特异性转移的动物模型深入研究肿瘤免疫微环境在LUAD转移中的生物学机制，探寻和开发能靶向肝转移灶肿瘤的潜在药物，对于提高LUAD肝转移患者的治疗效果和生存质量具有重要意义，然而目前尚缺乏用免疫完整小鼠建立的肺腺癌肝转移瘤模型。
发明内容
基于以上问题，本发明提供脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法，本发明首次创新的建立了肺腺癌肝转移小鼠模型。
为解决以上技术问题，本发明提供了脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法，步骤如下：
S1：制备表达荧光素酶基因luciferase的Lewis肺癌细胞单细胞悬浮液，其中细胞浓度为5×107/mL，后续每只小鼠的注射量为5×106个细胞/100μlPBS；
S2：准备4只6-8周龄的雄性C57BL/6J小鼠，进行脾脏注射，注射方式如下：
(1)给老鼠称重、麻醉备皮消毒，铺巾；
(2)切开左腹旁侧皮肤及肌肉；
(3)游离出脾脏，用一根4-0缝合线结扎脾脏中部，然后用手术电刀从结扎线一侧剪开脾脏，将脾脏分为两半；
(4)用胰岛注射针吸取步骤S1中的Lewis肺癌细胞悬浮液注射于(3)中分离出来的结扎的半个脾脏内，按照步骤S1中的注射量给每只小鼠注射100μl PBS细胞悬液，注射完成后等待3分钟后，将注射了Lewis肺癌细胞悬浮液的半个脾脏完全切除，将未注射Lewis肺癌细胞悬浮液的半个脾脏放回小鼠腹腔；
(5)补充腹水，缝合肌肉及皮肤，接种后第6、10、18天进行小动物活体成像证实形成肝转移灶，即肺腺癌肝转移小鼠模型。
进一步的，步骤S2(4)中Lewis肺癌细胞悬浮液的注射时间为3分钟。
与现有技术相比，本发明的有益效果是：本发明首次创新的建立了肺腺癌肝转移小鼠模型，该模型除肝组织外，其余器官均无转移瘤形成，为进一步研究肺腺癌肝转移的分子机制、信号调控途径，以及未来研究和开发抑制或/和阻断肺癌转移的分子靶向药物提供了可靠的动物模型。
附图说明
图1为本发明的脾内注射切除法建立肺癌肝转移模型示意图；
图2为本发明的实施例的脾内接种后肝转移模型小鼠的全身IVIS图像结果；
图3为本发明的实施例的肝转移瘤荧光强度定量；
图4为本发明的实施例中第18天时其他器官与肝脏内转移IVIS图像结果；
图5为本发明的实施例中第18天建立的实验性肝转移瘤HE染色结果图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白，下面结合实施例和附图，对本发明作进一步的详细说明，本发明的示意性实施方式及其说明仅用于解释本发明，并不作为对本发明的限定。
实施例：
本实施例提供了脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法，步骤如下：
S1：制备表达荧光素酶基因luciferase的Lewis肺癌细胞单细胞悬浮液(LLC-LUC)，其中细胞浓度为5×107/mL，后续每只小鼠的注射量为5×106个细胞/100μlPBS；
S2：准备4只6-8周龄的雄性C57BL/6J小鼠，进行脾脏注射，注射方式如下：
(1)给老鼠称重、麻醉备皮消毒，铺巾；
(2)切开左腹旁侧皮肤及肌肉；
(3)游离出脾脏，用一根4-0缝合线结扎脾脏中部，然后用手术电刀从结扎线一侧剪开脾脏，将脾脏分为两半；
(4)用胰岛注射针吸取步骤S1中的Lewis肺癌细胞悬浮液注射于(3)中分离出来的结扎的半个脾脏内，按照步骤S1中的注射量给每只小鼠注射100μlPBS细胞悬液，本实施例的Lewis肺癌细胞悬浮液的注射时间为3分钟，注射完成后等待3分钟后，将注射了Lewis肺癌细胞悬浮液的半个脾脏完全切除，将未注射Lewis肺癌细胞悬浮液的半个脾脏放回小鼠腹腔；
(5)补充腹水，缝合肌肉及皮肤。
本实施例于接种Lewis肺癌细胞悬浮液后第6、10、18天使用动物活体成像系统(IVIS)拍摄，拍摄前用DPBS(w/oMg2+、Ca2+)配置D-Luciferin工作液(15mg/mL)*，并经0.2μm滤膜无菌过滤，注射量：10μL/g的体重，如20g重小鼠，注射200μL工作液(1.5mgD-Luciferin)；腹腔注射10-15分钟后，上机进行图像分析。
见附图1，为本实施例的脾内注射切除法建立肝转移模型示意图，本实施例将未接种Lewis肺癌细胞悬浮液的老鼠作为空白对照组，见附图2，IVIS活体成像结果显示相比于对照组，4只接种LLC-LUC细胞的C57BL/6J小鼠于第6、第10、第18天均发生了肝转移，IVIS活体成像荧光强度值提示转移随时间延长而增多，从附图3中也可看出随着时间延长荧光强度变强。
LLC-LUC细胞接种C57BL/6J小鼠后第18天，处死小鼠并解离心、肝、脾、肺、肾、脑，进行荧光成像，见附图4和附图5，结果显示除肝组织外，其余器官均无转移瘤形成，代表本实施例成功构建了肺腺癌肝转移小鼠模型，HE染色也确证了接种LLC-LUC细胞的C57BL/6J小鼠肝脏出现了肝转移。
如上即为本发明的实施例。上述实施例以及实施例中的具体参数仅是为了清楚表述发明验证过程，并非用以限制本发明的专利保护范围，本发明的专利保护范围仍然以其权利要求书为准，凡是运用本发明的说明书及附图内容所作的等同结构变化，同理均应包含在本发明的保护范围内。
Claims (2)
1.脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法，其特征在于，步骤如下：
S1：制备表达荧光素酶基因luciferase的Lewis肺癌细胞单细胞悬浮液，其中细胞浓度为5×107/mL，后续每只小鼠的注射量为5×106个细胞/100μlPBS；
S2：准备4只6-8周龄的雄性C57BL/6J小鼠，进行脾脏注射，注射方式如下：
(1)给老鼠称重、麻醉备皮消毒，铺巾；
(2)切开左腹旁侧皮肤及肌肉；
(3)游离出脾脏，用一根4-0缝合线结扎脾脏中部，然后用手术电刀从结扎线一侧剪开脾脏，将脾脏分为两半；
(4)用胰岛注射针吸取步骤S1中的Lewis肺癌细胞悬浮液注射于(3)中分离出来的结扎的半个脾脏内，按照步骤S1中的注射量给每只小鼠注射100μlPBS细胞悬液，注射完成后等待3分钟后，将注射了Lewis肺癌细胞悬浮液的半个脾脏完全切除，将未注射Lewis肺癌细胞悬浮液的半个脾脏放回小鼠腹腔；
(5)补充腹水，缝合肌肉及皮肤，接种后第6、10、18天进行小动物活体成像证实形成肝转移灶，即肺腺癌肝转移小鼠模型。
2.根据权利要求1所述的脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法，其特征在于，步骤S2(4)中Lewis肺癌细胞悬浮液的注射时间为3分钟。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210791084.XA CN115281150A (zh) | 2022-07-05 | 2022-07-05 | 脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210791084.XA CN115281150A (zh) | 2022-07-05 | 2022-07-05 | 脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115281150A true CN115281150A (zh) | 2022-11-04 |
Family
ID=83821475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210791084.XA Pending CN115281150A (zh) | 2022-07-05 | 2022-07-05 | 脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115281150A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966087A (zh) * | 2006-07-25 | 2007-05-23 | 南京大学 | 一种小鼠原发性肝癌模型的建立方法 |
| US20160008399A1 (en) * | 2013-01-14 | 2016-01-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| CN107137425A (zh) * | 2017-05-22 | 2017-09-08 | 深圳市体内生物医药科技有限公司 | 一种循环肿瘤细胞小鼠模型、其构建方法及应用 |
| CN112166106A (zh) * | 2018-05-04 | 2021-01-01 | 韩国生命工学硏究院 | 通过抑制癌细胞迁移和侵袭的癌症转移抑制剂 |
| WO2021062051A1 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Tissue‑engineered 3d models for cancer metastasis |
| CN113264998A (zh) * | 2021-01-28 | 2021-08-17 | 四川大学华西医院 | 抗新冠病毒SARS-CoV-2表面S1蛋白的单链抗体及其应用 |
-
2022
- 2022-07-05 CN CN202210791084.XA patent/CN115281150A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966087A (zh) * | 2006-07-25 | 2007-05-23 | 南京大学 | 一种小鼠原发性肝癌模型的建立方法 |
| US20160008399A1 (en) * | 2013-01-14 | 2016-01-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| CN107137425A (zh) * | 2017-05-22 | 2017-09-08 | 深圳市体内生物医药科技有限公司 | 一种循环肿瘤细胞小鼠模型、其构建方法及应用 |
| CN112166106A (zh) * | 2018-05-04 | 2021-01-01 | 韩国生命工学硏究院 | 通过抑制癌细胞迁移和侵袭的癌症转移抑制剂 |
| WO2021062051A1 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Tissue‑engineered 3d models for cancer metastasis |
| CN113264998A (zh) * | 2021-01-28 | 2021-08-17 | 四川大学华西医院 | 抗新冠病毒SARS-CoV-2表面S1蛋白的单链抗体及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giavazzi et al. | Experimental nude mouse model of human colorectal cancer liver metastases | |
| AU2022100027A4 (en) | Method and device for screening drug | |
| CN110652492A (zh) | 一种载药外泌体及其应用、肝脏疾病药物 | |
| CN107760784A (zh) | 环状RNA circ‑FOXP1的用途 | |
| CN107345231A (zh) | 一种抑制EGFR基因表达的siRNA及其前体和应用 | |
| CN110755457A (zh) | 一种克服肿瘤耐药的方法 | |
| CN109563513A (zh) | 一种抑制K-RAS基因表达的siRNA及其前体和应用 | |
| CN111803493A (zh) | 马来酸替加色罗在制备抗肿瘤药物中的应用 | |
| CN112190712A (zh) | 氢巯基氧化酶1激动剂和索拉菲尼联合在制备治疗肝癌细胞中的应用 | |
| CN111298121B (zh) | Ctrp6基因缺失在抑制肿瘤生长中的应用 | |
| CN113528427A (zh) | 一种结直肠靶向载药外泌体及应用和治疗结直肠疾病药物 | |
| CN115281150A (zh) | 脾脏切除注射法建立肺腺癌肝转移小鼠模型的方法 | |
| JPH0723309B2 (ja) | 癌治療薬剤 | |
| CN102159709A (zh) | 用于恶性间皮瘤的新型治疗剂和免疫刺激剂 | |
| CN112661812B (zh) | 一种kk-lc-1抗原靶向结合肽及其衍生物、探针与应用 | |
| US20200296942A1 (en) | Peromyscus Animal Model for Cancer | |
| CN113952322A (zh) | Mmb在制备抗结直肠癌药物中的应用 | |
| CN114191539A (zh) | 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 | |
| KR102444740B1 (ko) | Ksp 억제제와 유사분열 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
| US20100247623A1 (en) | Cancer Stem Cell Vaccine | |
| WO2018000975A1 (zh) | 一种防治肿瘤的药物及其用途 | |
| CN107715103A (zh) | Clusterin在制备杀伤肿瘤干细胞的癌症治疗药物中的应用 | |
| CN114222753B (zh) | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 | |
| Wajsman et al. | A study of the effect of papaverine in neuroblastoma using the experimental C1300 murine system | |
| CN115029316B (zh) | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |